The role of tumor necrosis factor in sepsis (original) (raw)

Abstract

There is an increasing incidence of sepsis among hospitalized patients. Also, high mortality associated with sepsis and septic shock persists despite appropriate antibiotic therapy. Recent investigations have demonstrated that bacterial antigens stimulate a cascade of cellular mediators or cytokine release. In sepsis and septic shock the response of these cytokines often exceeds natural downregulation and leads to multisystem organ failure and even death in an unacceptably high number of patients. Many investigative studies have shown that tumor necrosis factor (TNF) is the prime mediator of the inflammatory response seen in sepsis and septic shock. Sepsis management in the future will include immune modulating therapy directed against the deleterious effects of cytokines, specifically TNF. This article reviews the current problem of sepsis and the evidence to support the role of TNF in sepsis. also, recent studies employing monoclonal antibodies against TNF as well as consideration...

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (42)

  1. Dinarello, C. A., Cannon J. G., Wolff S. M., et al., Tumor necrosis factor (cachectinl is an endogenous pyrogen and induces produc- tion of interleukin 1. J. Exp. Med. 163, 1433-1450, 1986.
  2. Michie, H. R., Spriggs, D. R., Manogue, K. R., et aE., Tumor ne- crosis factor and endotoxin induce similar metabolic responses in human beings. Surgery 104, 280-286, 198%.
  3. Warren, R. S., Starnes, F., Fabrilove, J. L., Oettgen, H. F., and Brennan, M. F., The acute metabolic effects of tumor necrosis factor in humans. Arch. Surg. 122, 1395-1400, 1987. 24, 25. Michie, H. R., and Wilmore, D. W., Sepsis, signals, and surgical sequelae (a hypothesis). Arch. Surg. 125, 531636, 1990.
  4. Parillo, J. E., Parker, M. M., Natanson, C., Suffredini, A, I'..
  5. Dunner, R. L., Cunnion, R. E., and Osnibene, F. P., Septic shock in humans. Ann. Intern. Med. 113, 227-242, 1990.
  6. Tracey, K. J., Beutler, B., Lowry, S. F., et al., Shock and tissue injury induced by recombinant human cache&in. Science 2.34% 470-474,19%6.
  7. Bauss, F., Droge, W., and Mannel, D. N., Tumor necrosis factor mediates endotoxic effects in mice. Infect. Zmmun. 55, L622- 1625, 1987. From the Centers for Disease Control, Increase in National Hos- pital Discharge Survey rates for septicemia-united States, 1979-1987. JAMA 263,937-938, 1990.
  8. Bone, R. C., Fisher, C. J., Clemmer, T. D., Slotman, G. J., Metz, C. A., and Baik, R. A., Sepsis syndrome: A valid clinical entity. Crit. Cure Med. 17, 389-393, 1989.
  9. Parker. M. M., and Parrillo, J. El., Septic shock Hemodynamics and pathogenesis. JAMA 250, 3324, 1983.
  10. Kreger, B. E., Craven, D. E., Carling, P. C., et al., Gram negative bacteremia. Reassessment of etiology, epidemiology and ecology in 612 patients. Am. J. Med. 63, 332, 1980.
  11. Pollack, M. M., Fields, A. I., and Ruttimann, U. E., Distributions of cardiopulmona~ variables in pediatric survivors and nonsur- vivors of septic shock. Grit. Care Med. 13, 454, 1985.
  12. Balk, R. A., and Bone, R. C., The septic syndrome: Definition and clinical implications. Crit. Care Clin. 5, 1-7, 1989.
  13. Carswell, E. A., Old, L. J.. Kassel, R. L., Green, S., Fiong, N.. and Williamson, B., An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. USA 72, 3666, 1975. Coley, W. B., The therapeutic value of the mixed toxms of the streptococcus of erysipelas and bacillus prodigiosus in the treat- ment of inoperable malignant tumors with a report of one hun- dred sixty cases. Am. J. Med. Sci. 112, 251, 1896.
  14. Coley. W. B., Contribution to the knowledge of sarcoma. The treatment of sarcoma by inoculation with erysipelas, with a re- port of three recent cases. Ann. Surg. 14, 199, 1891.
  15. Shear, M. J., and Turner, F. C., Reactions of mice with primary subcutaneous tumors to injections of hemorrhage producing bac- terial polysaccharide. J. N&l. Cancer Inst. 4. 461, 1943.
  16. Old, L. J., Tumor necrosis factor. Sci. Am. 25815), 9-75, 198%.
  17. Beutler, B., Mahoney, J., Le Trang, N., Pekala, P., and Cerami, A., Purification of cachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxin-induced RAW 264.7 cells. J. Exp Med. 161, 984-995, 1985.
  18. Beutler, B., and Cerami, A., Cachectin and tumor necrosis factor as two sides of the same biological coin. Nature 320, 584-588, 1986.
  19. Pennica, D., Nedwin, G. E., Hayflick, J. S., et aE., Human tumor necrosis factor: Precursor structure, expression and homolo~ to lymphotoxin. Nature 312, 724-729, 1984.
  20. Selby, P., Hobbs, S., Viner, C., et al., Tumor necrosis factor in man: Clinical and biological observations, Br. J. Cancer 56,803- 806,1987.
  21. Sherman, M. L., Spriggs, D. R., Arthur, K. A., et al., Recombi- nant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: Phase I toxicity and ef- fects on lipid metabolism. J. Clin. Oncol. 6(2), 344-350, 1988.
  22. Michie, H. R., Manogue, K. R., Spriggs, D. R., et OZ., Detection of circulating tumor necrosis factor after endotoxin administra- tion. N. Engl. J. Med. 318, 1481-1486, 198%. Aggarwal, B. B., Characterization of receptors for human tumor necrosis factor and their regulation by gamma-interferon, Nu- ture 318, 665-667, 1985.
  23. Kunkel, S. L., Spengler, M., May, M. A., Spengler, R., Larrick, J. W., and Remick, D., Prostaglandin Ez regulates macrophage- derived tumor necrosis factor gene expression. J. Biol. Chem. 263, 5380, 1988.
  24. Ibid. Essner, R., Rhoades, K., McBride, W. H., Morton, D. L., and Economou, J. S., IL-4 downregulates IL-1 and TNF gene expres- sion in human monocytes. J. Zmmunol. 142,3857-3861, 1989.
  25. Espevik, T., Figari, I. S., Shalaby, M. R., Lackides, G. A., Lewis, G. D., Shepard, H. M., and Palladino, M. A., Inhibition of cyto- kine production by cyclosporin A and transforming growth fac- tor-beta. J. Exp. Med. 166, 571-576, 1987.
  26. Takayama, T. K., Miller, C., and Szabo, G., Elevated tumor ne- crosis factor alpha production concomitant to elevated prosta- glandin E, production by trauma patients' monocytes. Arch.
  27. SUFg. 125, 29-35, 1990.
  28. Tracey, K. J., and Beutler, B., Shock and tissue injury induced by recombinant human cachectin. Science 234, 47-73, 1986.
  29. Bauss, F., Droge, W., and Mannel, D. N., Tumor necrosis factor mediates endotoxic effects in mice. Infect. Zmmun. 55, 1622- 1625,1987.
  30. Tracey, K. J., Beutler, B., and Cerami, A., Cachectinltumor ne- crosis factor induces lethal shock and stress hormone responses in the dog. Surg. Gynecol. Obstet. 164, 415422, 1987.
  31. Ibid.
  32. Waage, A., and Espevik, T., Association between tumor necrosis factor in serum and fatal outcome in patients with meningococ- cal disease. Lancet 319, 355-357, 1987.
  33. Girardin, E., Grau, G. E., Dayer, J. M., et al., Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. N. Engl. J. Med. 319, 3971100, 1988.
  34. Debets, J. M., Kampmeijer, R., van der Linden, M. P., et al., Plasma tumor necrosis factor and mortality in critically ill sep- tic patients. Crit. Cure Med. 17(6), 489494, 1989.
  35. Damas, P., Reuter, A., Gysen, P., et al., Tumor necrosis factor 39. 40. 41. 42. 43. 44. 45. 46. and interleukin-1 serum levels during severe sepsis in humans. Crit. Care Med. 17(10), 975-978, 1989.
  36. Marks, J. D., Marks, C. B., Lute, J. M., et al., Plasma tumor necrosis factor in patients with septic shock: Mortality rate, in- cidence of adult respiratory distress syndrome. Am. Rev. Respir. Dia. 141, 9P97, 1990.
  37. Beutler, B., Milsark, I. W., and Cerami, A. C., Passive immuni- zation against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 229, 869-871, 1985. Opal, S. M., Cross, A. S., Kelley, N. M., Sadoff, J. C., Bodmer, M. W., Palardy, J. E., and Victor, G. H., Efficacy of a monoclonal antibody directed against TNF in protecting neutropenic rats from lethal infection with P. ueruginosu. J. Infect. Dis. 161, 11481152,199O.
  38. Silva, A. T., Bayston, K. F., and Cohen, J., Prophylactic and therapeutic effects of a monoclonal antibody to TNF-alpha in experimental gram-negative shock. J. Infect. Dis. 162, 421-427, 1990.
  39. Tracey, K. J., Fong, Y., Hesse, D. G., Manogue, K. R., Lee, A. T., and Kuo, G. C., Anti-cachectinfTNF monoclonal antibodies pre- vent septic shock during lethal bacteremia. Nature 330, 662- 664, 1987.
  40. Fong, Y., Tracey, K. J., Moldawer, L. L., Hesse, D. G., Manogue, K. R., and Kenney, J. S., Antibodies to cachectimTNF reduce interleukin-l-beta and interleukin-6 appearance during lethal bacteremia. J. Ezp. Med. 170, 1627-1633, 1989.
  41. Hinshaw, L. B., Tekamp-Olson, P., Chang, A. C. K., Lee, P. A., Taylor, F. B., Jr., Murray, C. K., Peer, G. T., Emergon, T. E., Jr., Poassey, R. B., and Juo, G. C., Survival of primates in LD,,, septic shock following therapy with antibody to tumor necrosis factor (TNF-alpha). Circ. Shock 30, 279-292, 1990.
  42. Exley, A. R., Cohern, J., Buurman, W., Owen, R., Lumley, J., Hanson, G., Aulakh, J. M., Bodner, M., Riddell, A., Stephens, S., and Perry, M., Monoclonal antibody to TNF in severe septic shock. Lancet 335, 1275-1276,199O.